Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2022

View Archived Issues

Discovery of potent tubulin polymerization inhibitor with promising anticancer activity

Novel immune-competent mouse model of acute myeloid leukemia

Code Biotherapeutics raises series A financing to advance programs for genetic diseases

PineTree Therapeutics to advance oncology and viral diseases platforms

Biogen and Alectos enter license and collaboration agreement for GBA2 inhibitor for Parkinson's

Southern Research Institute and UABRF report development of HO-1 modulators

University of California and University of Washington divulge IRE1 inhibitors

Foghorn Therapeutics describes SNF2L2/BRG1 inhibitors

Janssen Pharmaceutica discloses MAP3K14 inhibitors

Korean research groups patent novel antioxidants

Prognostic biomarkers of atherosclerosis and cardiovascular disease in patients with SLE

CiPA used to validate Axol's iPSC-derived ventricular cardiomyocytes for cardiac safety testing

Find Therapeutics and SATT Conectus sign licensing agreement for new approach to treat MS

Targeting NLRP3 inflammasome pathway prevents C. septicum-induced lethality

Kiromic enters SRA with MD Anderson to support IND filings for gamma delta T-cell product candidates

Coya raises financing to advance Treg-derived exosome therapeutics into clinic

WNT plays dual role in melanoma spread to lung

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...